论文部分内容阅读
目的：分析熊去氧胆酸（优思弗）治疗药物性肝损伤的临床疗效及其安全性。方法：回顾性汇总分析60例临床诊断药物性肝损的住院患者，按是否应用优思弗将患者分为两组：优思弗组(30例)和对照组(30例)，统计分析两组患者治疗前后的临床特征、各项生化等指标并进行统计学分析。结果：两组患者治疗前肝功能无显著差异。二组在治疗前后ALT、AST、TBil对比均存在差异，两组间治疗后肝功能比较，ALT、AST、TBil存在差异。在胆汁淤积型和混合型患者中治疗前后的TBil、GGT、ALP存在统计学差异。而在肝细胞损伤型患者中治疗前后ALT、AST存在统计学差异。优思弗组治疗后16例患者显效，12例患者有效，2例无效，总有效率93.3%，对照组8例显效，12例有效，10例无效，总有效率66.7%，两组疗效对比有明显的统计学差异。结论：熊去氧胆酸可以改善各型药物性肝损的临床症状和肝功能指标，且其不良反应少，是目前治疗药物性肝损的重要选择。“,”Objective To explore the curative effect and safety of ursodeoxycholic acid(UDCA) in treating drug-inducedliverinjury(DILI).Method Sixty cases of DILI patients in hospital were retrospectively analyizedm. Al cases were divided into the control group (30 cases) and the observation group(30 cases).The observation group was given UDCA additional y. The score of clinical feature and biochemistry index were compared between the two groups. Results There were no significant difference in the liver function between two group patients before treatment, The ALT、AST、TBil level of two groups were Statistical differences than that of the groups before treatment .The TBil level of patients with Cholestasis and patients with mixed type after treatment were Statistical differences than that of the patients before treatment . The ALTAST level of patients with hepatocel uar injury after treatment were statistical differences than that of the patients before treatment . Clinical analysis, In the treatment group, 16 cases were significantly improved, 12 cases were improved and 2 cases were invalid. The total effective rate was 93 %. When come to control group, the dates were 8,2,10 respectively , and the total effective rate was 63 %. There exist ‐ ed significant difference in t therapeutic effect between the two groups Conclusion UDCA can obviously improved the clinical symptoms and liver function of the DILI patients,and fewer side effects,UDCA is currently the fundamental choice with therapy for chronic myeloid leukemia.